This phase II/III trial is testing a new drug (ADI-PEG 20) in combination with standard chemotherapy for patients with pleural mesothelioma.
This trial is treating patients with mesothelioma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Eligible patients will be randomised to receive 36 mg/m2 of weekly ADI-PEG 20 or a placebo, in combination with pemetrexed (500mg/m2) and cisplatin (75mg/m2) which will be administered intravenously every three weeks.
Recruiting Hospitals Read More